
Survodutide Shines: Dual GLP-1/Glucagon Agonist Shows Major Weight Loss
Zealand Pharma and Boehringer Ingelheim announced breakthrough Phase 3 results for survodutide, a dual GLP-1 and glucagon receptor agonist, demonstrating significant weight reduction and metabolic improvements in adults with obesity or overweight.







